(Press-News.org) (Singapore, September 11, 2023, 10:05 a.m. SGT) – Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed chemotherapy alone, according to research presented today the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The UK Multicentre Randomised Trial, known as MARS 2, conducted by a team led by Professor Eric Lim from The Royal Brompton Hospital, United Kingdom, investigated the impact of extended pleurectomy decortication combined with chemotherapy compared to chemotherapy alone in patients with mesothelioma.
Mesothelioma, a rare and aggressive cancer primarily linked to asbestos exposure, has prompted exploration into various treatment options, including surgical procedures like pleurectomy decortication. However, despite its common use, the effectiveness of this intervention has never been evaluated in a randomized trial.
The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy (platinum and pemetrexed) or chemotherapy alone. The researchers followed patients for a median 22.4 months.
Patients randomized to surgery and chemotherapy exhibited a median survival of 19.3 months, while those randomized to chemotherapy alone demonstrated a median survival of 24.8 months. However, the hazards for death were non-proportional, prompting the presentation of primary outcomes in two timeframes: randomization to 42 months and beyond 42 months. The analysis indicated a 28% increase in the risk of death in the surgery group within the first 42 months, while no significant difference in survival emerged after 42 months, Lim reported.
Moreover, the research unveiled significant disparities in progression-free survival and adverse events between the two groups. The surgery group experienced a 3.6-fold higher incidence of serious adverse events (CTCAE grade 3 and above), and Dr. Lim reported that patients who underwent surgery reported poorer quality of life and well-being on various EORTC health-related quality of life scales, particularly in global health, physical functioning, social functioning, and role functioning. The surgery group also exhibited worse positive symptom scores, including pain, dyspnea, insomnia, loss of appetite, and financial difficulties.
Prof. Lim concluded that extended pleurectomy decortication should not be offered to patients with pleural mesothelioma and classifying this disease as “unresectable” from the outset would increase access to more effective systemic treatments to improve survival for patients with early-stage disease.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
END
MARS trial: decortication and chemotherapy associated with worse outcomes for patients with resectable mesothelioma
2023-09-11
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Large-scale investigation supports modified classification system for pulmonary adenocarcinomas
2023-09-11
(Singapore – 10:05 a.m. SGT--September 11, 2023) – A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The study, led by Dr. Erik Thunnissen, Department of Pathology, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands, ...
Taiwan launches National Lung Cancer Early Detection Program detects 85 percent of lung cancer cases at early phase
2023-09-11
First-ever National Screening Program to Consider Family History
(Singapore – 10:05 a.m. SGT--September 11, 2023) – The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
The results of the program were presented by Pan-Chyr Yang, MD, PhD from the National Taiwan University Hospital, at the International Association for the Study of Lung Cancer 2023 World Conference ...
Surgical outcomes of perioperative durvalumab in AEGEAN study to be presented at IASLC 2023 World Conference on Lung Cancer
2023-09-11
[Singapore, 10:05 a.m. SGT--September 11, 2023] – Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
"The AEGEAN trial demonstrated a clinically meaningful improvement in EFS ...
Treatment for dangerous snoring prevents deaths from heart disease
2023-09-11
Milan, Italy: People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying from cardiovascular disease if they use a continuous positive airway pressure (CPAP) machine at night, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
CPAP may also work better than a weight loss drug in reducing the build-up of plaque in the arteries around the heart, according to a pilot study also presented at the European Respiratory Society International Congress [2].
People with OSA often snore loudly, their breathing starts and stops during the night, and they may ...
City living raises the risk of respiratory infections in babies and young children
2023-09-11
Milan, Italy: Young children growing up in towns and cities suffer from more respiratory infections than those who grow up in the countryside, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
A second study, presented at the Congress and published in Pediatric Pulmonology today (Monday) [2], shows that factors such as attending day care, living in a damp home or near dense traffic increase the risk of chest infections in young children, while breastfeeding reduces the risk.
Researchers say that some children, who are otherwise healthy, can suffer with repeated infections, so it is important to understand why ...
Healthy guts containing diverse and mature bacteria are linked to less allergy-related wheezing and asthma in early childhood
2023-09-10
Milan, Italy: Babies and young children with more mature communities of bacteria present in their gut are less likely to develop allergy-related wheezing or asthma, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
These communities of bacteria, known as microbiota, develop in the human body during the early years of life and are involved in processes that are helpful to the body, such as synthesising vitamins and boosting the immune system, or occasionally unhelpful, such as the role they play ...
Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension
2023-09-10
About The Study: Among individuals with uncontrolled hypertension in this randomized clinical trial that included 200 participants, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.
Authors: Steven E. Nissen, M.D., of the Cleveland Clinic Foundation, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.16029)
Editor’s Note: Please see the article for additional ...
Benmelstobart plus anlotinib and chemotherapy shows benefit for patients with extensive-stage small-cell lung cancer
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] - The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage small-cell lung cancer.
The research was presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
Extensive-stage small-cell lung cancer is a challenging malignancy to treat, ...
Exhaled breath analysis shows promise in detecting malignant pleural mesothelioma
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] -- Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Malignant pleural mesothelioma (MPM) is a challenging disease with limited treatment options and a poor prognosis. To improve ...
Six-year follow-up data on CheckMate 227 survival and quality of life benefits unveiled for patients with metastatic NSCLC and nivolumab + ipilimumab treatment
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023) -- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment. Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
CheckMate 227 Part 1 showed that a combination ...